Form 8-K - Current report:
SEC Accession No. 0001193125-25-132301
Filing Date
2025-05-30
Accepted
2025-05-30 17:15:02
Documents
16
Period of Report
2025-05-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d42374d8k.htm   iXBRL 8-K 57604
2 EX-3.1 d42374dex31.htm EX-3.1 5758
3 EX-10.1 d42374dex101.htm EX-10.1 308607
4 EX-99.1 d42374dex991.htm EX-99.1 9963
8 GRAPHIC g42374g0530220014730.jpg GRAPHIC 3637
  Complete submission text file 0001193125-25-132301.txt   558834

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fate-20250529.xsd EX-101.SCH 2877
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20250529_lab.xml EX-101.LAB 17980
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20250529_pre.xml EX-101.PRE 11276
19 EXTRACTED XBRL INSTANCE DOCUMENT d42374d8k_htm.xml XML 3746
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 251012208
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)